Generic medicines: Perceptions of community pharmacists in Melbourne, Australia

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 14, Issue 3, 2005, Pages 27-45

  Hassali, Mohamed Azmi ^a   Kong, David C M ^a,b   Stewart, Kay ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Brand substitution; Generic medicines; Medicine cost; Perceptions; Pharmacists

Indexed keywords

GENERIC DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CONTENT ANALYSIS; DRUG COST; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HUMAN; MALE; PATIENT EDUCATION; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; SEMI STRUCTURED INTERVIEW;

EID: 33744962384     PISSN: 15385698     EISSN: 15385396     Source Type: Journal    
DOI: 10.1300/J371v14n03_03     Document Type: Article

References (48)

1. Commonwealth Department of Health and Ageing. The National Medicines Policy 2000. Canberra: Commonwealth Department of Health and Aged Care; 1999.
2. Carroll N.V. Impact of generic and therapeutic interchange incentives on community pharmacy. Am Pharm 1995; NS35 (7): 27-34.
3. Karim S., Pillai G., Ziqubu-Page T.T., Cassimjee M.H., Morar M.S. Potential savings from generic prescribing and generic substitution in South Africa. Health Policy Plan 1996; 11 (2): 198-205.
4. Kirking D.M., Ascione F.J., Gaither C.A., Welage L.S. Economics and structure of the generic pharmaceutical industry. J Am Pharm Assoc 2001; 41 (4): 578-84.
5. King D.R., Kanavos P. Encouraging the use of generic medicines: Implications for transition economies. Croat Med J 2002; 43 (4): 462-9.
6. Lofgren H. Generics drugs: International trends and policy developments in Australia. Aust Health Rev 2004; 27 (1): 39-48.
7. Ioannides-Demos L.L., Ibrahim J.E., McNeil J.J. Reference-based pricing schemes-Effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002; 20 (9): 577-91.
8. McGavock H. Strategies to improve the cost effectiveness of general practitioner prescribing. An international perspective. Pharmacoeconomics 1997; 12 (3): 307-11.
9. McGavock H. Generic substitution: Issues relating to the Australian experience. Pharmacoepidemiol Drug Saf 2001; 10 (6): 555-6.
10. Smeaton J. The generics market. Aust J Pharm 2000; 81: 540-42.
11. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 (2): 89-103.
12. Fischer M.A., Avorn J. Economic consequences of underuse of generic drugs: Evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 2003; 38 (4): 1051-64.
13. Ford N., Hoen E. Generic medicines are not substandard medicines. Lancet. 2002; 359 (9314): 1351.
14. Gaither C.A., Kirking D.M., Ascione F.J., Welage L.S. Consumer's views on generic medications. J. Am Pharm Assoc 2001; 41 (5): 729-36.
15. Campbell M., Smith M., Beaney A. The pros and cons of generic medicines. Pharmacoeconomics 1995; 8 (4): 362-4.
16. Scuderi M. Generic substitution in a Brisbane community pharmacy. Aust Pharm 2002; 21: 116-21.
17. Tatchell M. Controlling drug expenditure. Aust J Pharm 2003; 84 (March): 229.
18. Mott D.A., Cline R.R. Exploring generic drug use behavior: The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 2002; 40 (8): 662-74.
19. Pharmaceutical Society of Australia. Guidelines on pharmaceutical benefits scheme brand substitution. In: Sansom L., editor. Australian Pharmaceutical Formulary and Handbook. 19th ed. Canberra: Pharmaceutical Society of Australia; 2004. p. 388.
20. Kirking D.M., Gaither C.A., Ascione F.J., Welage L.S. Pharmacists' individual and organizational views on generic medications. J Am Pharm Assoc 2001; 41 (5): 723-28.
21. Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners Effective From 1 February 2005. Canberra: National Capital Printing; 2005.
22. Glazer B.C., Strauss A.L. The Discovery of Grounded Theory: Strategies for Qualitative Research. New York: Aldine; 1967. p. 67.
23. Berg B. Designing qualitative research. In: Qualitative Research Methods for the Social Sciences. 5th ed. Boston: Allyn & Bacon; 1998. p. 37.
24. Quine S. Sampling in non-numerical research. In: Kerr C., Taylor R., Heard G., editors. Handbook of Public Health Methods. Sydney: McGraw-Hill; 1998. pp. 539-41.
25. Smith F. Qualitative interviews. In: Research Methods in Pharmacy Practice. London: Pharmaceutical Press; 2002. pp. 119-22.
26. Quine S. Interviews. In: Kerr C., Taylor R., Heard G., editors. Handbook of Public Health Methods. Sydney: McGraw-Hills; 1998. pp. 522-26.
27. Pope C., Ziebland S., Mays N. Analysing qualitative data. BMJ 2000; 320: 114-116.
28. Mays N., Pope C. Qualitative research: Rigour and qualitative research. BMJ 1995; 311: 109-12.
29. Quality Care Pharmacy Program. About the Quality Care Pharmacy Program. Available at: http://www.qcpp.com/about_QCPP.htm. Accessed June 30, 2003.
30. Pharmacy Guild of Australia. About the Pharmacy Guild of Australia. Available at: http://www.guild.org.au/public/aboutguild.asp. Accessed June 30, 2003.
31. Pharmaceutical Benefits Pricing Authority. Annual report for the year ended 30 June 2003. Canberra: Australian Government Printing Service; 2003. pp. 4-5.
32. Hollis A. The anti-competitive effects of brand controlled "pseudo-generics" in the Canadian pharmaceutical market. Can Public Policy 2003; 29 (1): 21-31.
33. Probyn A. Some drugs more equal than others: Pseudo-generics and commercial practice. Aust Health Rev 2004; 28 (2): 207-17.
34. Nation R., Sansom L. Bioequivalence requirements for generic products. Pharmac Ther 1994; 62: 41-55.
35. Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners Effective From 1 February 2005. In. Canberra: National Capital Printing; 2005. p. 74.
36. Therapeutics Goods Administration. Note For Guidance on Investigation of Biovailability and Bioequivalence. Canberra: Therapeutic Goods Administration; 2002. pp. 1-18.
37. Birkett D.J. Generics equal or not? Aust Prescr 2003; 26 (4): 85-7.
38. Sanderson J., Lewis J. Differences in side-effect incidence in patients on proprietary and generic propranolol. Lancet 1986; 26: 967-68.
39. Locniskar A., Greenblatt D., Harmatz J., Shader R. Bioinequivalence of generic brand of diazepam. Biopharm Drug Dispos 1989; 10: 597-605.
40. Lesser R.P., Krauss G. Buy some today: Can generics be safely substituted for brand-name drugs? Neurology 2001; 57 (4): 571-3.
41. Sweeny K. Trends in the Use and Cost of Pharmaceuticals Under the Pharmaceutical Benefits Scheme. Working Paper No. 5. Pharmaceutical Industry Project Equity, Sustainability and Industry Development Working Paper Series. Melbourne: Centre for Strategic Economic Studies, Victoria University of Technology; 2002. pp. 1-26.
42. Sorensen L. Medication misadventure risks-findings at home visits. In: Hodgson W.C., Loicano R.E., editors. Proceedings of the Annual Australian Society of Clinical and Experimental Pharmacologists and Toxicologists; 2000 Dec 3-6; Newcastle, Australia, p. 100.
43. Therapeutics Goods Administration. Review of the Labelling Requirements For Medicines: Consumer-focused Labelling-A Way Forward. Available at: http://www.health.gov.au/tga/docs/html/labelrev.htm. Accessed on 30th July 2003.
44. Segal R., Wantz D., Brusadin R. Pharmacists' decision making in the selection of generic pharmaceuticals. J Pharm Mark Manage 1989; 4 (1): 75-91.
45. Sanborn M.D., White S.J. Pharmacists' perceptions and practices regarding the purchase of multisource pharmaceuticals. Hosp Pharm 1993; 28 (2): 104-6, 109-13.
46. Lundin D. Moral hazard in physician prescription behavior. J Health Econ 2000; 19 (5): 639-62.
47. Rosendahl I. Consumers on generics: Some clues on their views from AARP. Drug Topics 1994; Suppl (May): 54S-56S.
48. Knowlton C., Knapp D. Community pharmacists help HMO cut drug costs. American Pharmacy 1994; NS34 (1): 36-42.